2169919-21-3
- Product Name：SNDX-5613
- Molecular Formula：C32H47FN6O4S
- Purity：99%
- Molecular Weight：630.82
Product Details:
CasNo： 2169919-21-3
Molecular Formula： C32H47FN6O4S
Appearance： White to off-white Solid
Delivery Time： 2 weeks after order
Throughput： 100KG/Month
Purity： 99%
Synonyms: Benzamide, N-ethyl-2-[[4-[7-[[trans-4-[(ethylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-5-fluoro-N-(1-methylethyl)-; SNDX5613; Revumenib; N-Ethyl-2-((4-(7-((trans-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide
Boiling point: 739.1±70.0 °C
Density: 1.28±0.1 g/cm3
Solubility: DMSO:30.0(Max Conc. mg/mL);47.56(Max Conc. mM)
Pka: 11.10±0.40
Uses:
SNDX-5613 (Revumenib) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. SNDX-5613 (Revumenib) can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
Relevant Products
-
FezolinetantCAS：1629229-37-3
-
RV521CAS：1903763-82-5
-
SirpiglenastatCAS：2079939-05-0
